- Home
- Applications
- USA
- disease progression
Show results for
Refine by
Disease Progression Product Applications In Usa
18 applications found
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ...
ByOtsuka America Pharmaceutical, Inc based in Princeton, NEW JERSEY (USA)
Providers sometimes can correct heart failure by treating the underlying cause. For example, repairing a heart valve or controlling a fast heart rhythm may reverse heart failure. But for most patients, heart failure is a chronic disease needing lifelong management. Nowadays, with appropriate treatment, signs and symptoms of heart failure can improve, and the heart can sometimes even regain strength. For many patients, the treatment of heart failure involves a balance of being prescribed the right medications, but ...
ByImpulse Dynamics based in Marlton, NEW JERSEY (USA)
Your liver responds to many diseases that damage its cells by developing scar tissue or fibrosis. If poked, a healthy liver is very soft. Alternatively, a liver that has developed fibrosis is firmer, and if the condition progresses to cirrhosis, the liver can be almost ...
ByResoundant, Inc. based in Rochester, MINNESOTA (USA)
Heart Failure may start suddenly, and you may feel symptoms immediately, or it may start slowly and progress unnoticed for some time. Some patients do not realize that they have heart failure because they believe that their symptoms are just indications of getting older. The condition typically starts after there is some sort of injury to the heart muscle (e.g. a heart attack), and over time, the unusual stresses placed on the heart muscle cause the disease to ...
ByImpulse Dynamics based in Marlton, NEW JERSEY (USA)
As the COVID-19 pandemic continues, the SARS-CoV-2 virus is likely to become endemic with emerging novel variants, some of them seasonal. Updates to the various vaccines will be required, as will a range of anti-virals with a variety of mechanisms of action, for use in early infection and in hospitalizated patients, much like oseltamivir (Tamiflu) is used in certain populations for seasonal ...
ByCyrus Biotechnology Inc. based in Seattle, WASHINGTON (USA)
The presence of a nodule in your lung, more commonly known as a mass or “spot” on your lungs, can be quite scary. However, a lung nodule or mass is a lot more common than you might think. Many nodules are benign, meaning that they are not cancer. It is important to know what type of lung nodule you have. ...
ByAuris Health, Inc. based in Redwood City, CALIFORNIA (USA)
The influence of human gut microbiota on our health is an exciting and expanding frontier of research. New discoveries are published frequently underscoring the power and influence of these tiny organisms and their ecosystems over our every-day lives. Understanding this power, and how it can be harnessed to restore health or prevent disease, has been the guiding force for Rebiotix since its founding in ...
ByRebiotix Inc., a Ferring Company based in Roseville, MINNESOTA (USA)
A high incidence of thromboembolic complications leading to organ-failure, stroke, pulmonary embolism (PE) and deep vein thrombosis (DVT) have been reported in asymptomatic, symptomatic, and recovering patient groups. ...
ByAbram Scientific, Inc. based in Menlo Park, CALIFORNIA (USA)
With Qynapse we all benefit from earlier and more accurate monitoring of patients. Patients, practitioners, researchers and you – the payer, all benefit from earlier, more accurate central nervous system disease diagnosis and monitoring of patients throughout the care continuum. Qynapse has the potential to help lower costs, drive up quality outcomes and improve patient satisfaction. Are you ready to transform neuroscience with us? ...
ByQynapse based in Paris, FRANCE
In the most advanced stages of heart failure, in some cases, doctors recommend surgery to treat the disease. Heart Transplant & Ventricular Assist Devices are included in this category. These therapies are often a last option for patients with the most severe forms of heart ...
ByImpulse Dynamics based in Marlton, NEW JERSEY (USA)
Once medications lose effectiveness and symptoms begin to reappear, you may experience declining quality of life. At this point your provider may consider a device called Optimizer® Smart that is designed to improve contraction of the heart, allowing more oxygen-rich blood to reach the body. The Optimizer® Smart system delivers Cardiac Contractility Modulation therapy which is a new therapeutic approach that improves quality of life for patients that are no longer adequately responding to medications ...
ByImpulse Dynamics based in Marlton, NEW JERSEY (USA)
Automated MRI analyses that may help inform earlier, more accurate viewsof CNS disease, such as Alzheimer’s, Parkinson’s and multiple sclerosis. For healthcare providers on the frontlines of diagnosing and treating central nervous system disease, and for your patients, Qynapse brings groundbreaking peace of mind by providing results you can trust through its flagship solution, QyScore. ...
ByQynapse based in Paris, FRANCE
Traditionally, primary treatment for DVT has focused on anticoagulation, rather than thrombus removal. Anticoagulation therapy does not remove existing thrombus but rather prevents the propagation of the ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)
RVO is a chronic condition of the eye in which small blood clots form in the small veins that carry blood away from the retina. When this occurs, there is hemorrhage of blood from the blocked vessels into the surrounding retinal tissue leading to swelling (macular edema) and formation of new blood vessels (neovascularization). Left untreated, RVO typically leads to progressive deterioration of vision leading to permanent blindness. Risk factors for RVO include atherosclerosis, diabetes and high blood pressure. ...
ByCerevast Medical, Inc. based in Bothell, WASHINGTON (USA)
ATIVA’s rapid low-cost COVID-19 test may provide earlier detection and a safer community. The greatest challenge we face is the spread of infection before symptoms appear. We all want to protect our loved ones, so how do we know if we are carrying the virus? Physical symptoms (fever, cough) appear too late to stop the spread. The nasal swab PCR tests suffer from sampling errors, slow time to results, and are expensive. Early detection of infected people is the key to protecting our most vulnerable people in ...
ByAtiva Medical based in Shoreview, MINNESOTA (USA)
SARS-CoV-2 currently has the world in its grasp. A quick, non-invasive test to identify an infection would be a tremendous step forward. There is a high probability that this disease can be detected in the exhaled breath but also monitoring the impact of treatment or medication in exhaled breath is highly relevant. IONICON PTR-TOF systems have become the de-facto standard for real-time breath analysis. Learn what they offer for COVID-19 detection in ...
ByIonicon Analytik Ges.m.b.H. based in Innsbruck, AUSTRIA
Endovascular clot removal methods can provide immediate symptom relief and, by removing clot early, physicians can identify an underlying obstructive lesion that may require a stent. Current endovascular treatment methods involve catheter-directed thrombolysis (CDT), percutaneous mechanical thrombectomy (PMT), balloon venoplasty, iliac vein stenting, and manual ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)